Arrowhead Pharmaceuticals, a biopharmaceutical company focused on developing targeted RNA interference (RNAi) therapeutics, saw its stock plummet 5.08% in Wednesday's intraday trading session. This significant decline followed the company's disappointing first-quarter 2025 earnings report, which missed analysts' expectations and showcased widening losses.
The key financial highlights from the report were:
Despite the challenging quarter, Arrowhead Pharmaceuticals remains optimistic about its future growth prospects. The company forecasts a 42% annual revenue growth rate on average for the next three years, outpacing the projected 21% growth for the broader US biotechnology industry.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.